vs
PARK NATIONAL CORP（PRK）与Ultragenyx Pharmaceutical Inc.（RARE）财务数据对比。点击上方公司名可切换其他公司
Ultragenyx Pharmaceutical Inc.的季度营收约是PARK NATIONAL CORP的1.2倍（$207.3M vs $168.3M），PARK NATIONAL CORP净利率更高（25.3% vs -62.0%，领先87.4%），Ultragenyx Pharmaceutical Inc.同比增速更快（25.9% vs 2.2%），PARK NATIONAL CORP自由现金流更多（$191.9M vs $-100.8M），过去两年Ultragenyx Pharmaceutical Inc.的营收复合增速更高（38.0% vs 4.9%）
国家零售系统公司（NRS）旗下包含基石货运公司与国家零售运输公司，是一家成立于1952年的资产型第三方物流服务商，总部位于美国新泽西州林德赫斯特，为客户提供专业的物流供应链相关解决方案。
Ultragenyx Pharmaceutical Inc.是一家总部位于美国的生物制药企业，专注于研发罕见病和超罕见遗传病的创新治疗方案，这类疾病目前大多无获批疗法，存在大量未被满足的临床需求。公司覆盖生物制剂、小分子药物、基因疗法、反义寡核苷酸及mRNA等多种药物技术平台，研发管线涵盖骨骼、内分泌、代谢、肌肉及中枢神经系统疾病领域。
PRK vs RARE — 直观对比
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $168.3M | $207.3M |
| 净利润 | $42.6M | $-128.6M |
| 毛利率 | — | — |
| 营业利润率 | — | -54.7% |
| 净利率 | 25.3% | -62.0% |
| 营收同比 | 2.2% | 25.9% |
| 净利润同比 | 10.4% | 3.5% |
| 每股收益（稀释后） | $2.62 | $-1.28 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $168.3M | $207.3M | ||
| Q3 25 | $169.5M | $159.9M | ||
| Q2 25 | $168.7M | $166.5M | ||
| Q1 25 | $157.9M | $139.3M | ||
| Q4 24 | $164.7M | $164.6M | ||
| Q3 24 | $170.3M | $139.5M | ||
| Q2 24 | $157.7M | $147.0M | ||
| Q1 24 | $152.8M | $108.8M |
| Q4 25 | $42.6M | $-128.6M | ||
| Q3 25 | $47.2M | $-180.4M | ||
| Q2 25 | $48.1M | $-115.0M | ||
| Q1 25 | $42.2M | $-151.1M | ||
| Q4 24 | $38.6M | $-133.2M | ||
| Q3 24 | $38.2M | $-133.5M | ||
| Q2 24 | $39.4M | $-131.6M | ||
| Q1 24 | $35.2M | $-170.7M |
| Q4 25 | — | -54.7% | ||
| Q3 25 | 34.3% | -106.9% | ||
| Q2 25 | 35.2% | -64.8% | ||
| Q1 25 | 32.4% | -102.6% | ||
| Q4 24 | — | -74.3% | ||
| Q3 24 | 27.4% | -94.6% | ||
| Q2 24 | 30.6% | -79.1% | ||
| Q1 24 | 27.8% | -151.9% |
| Q4 25 | 25.3% | -62.0% | ||
| Q3 25 | 27.8% | -112.8% | ||
| Q2 25 | 28.5% | -69.0% | ||
| Q1 25 | 26.7% | -108.5% | ||
| Q4 24 | 23.5% | -80.9% | ||
| Q3 24 | 22.4% | -95.7% | ||
| Q2 24 | 25.0% | -89.5% | ||
| Q1 24 | 23.0% | -156.8% |
| Q4 25 | $2.62 | $-1.28 | ||
| Q3 25 | $2.92 | $-1.81 | ||
| Q2 25 | $2.97 | $-1.17 | ||
| Q1 25 | $2.60 | $-1.57 | ||
| Q4 24 | $2.38 | $-1.34 | ||
| Q3 24 | $2.35 | $-1.40 | ||
| Q2 24 | $2.42 | $-1.52 | ||
| Q1 24 | $2.17 | $-2.03 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $233.5M | $421.0M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $1.4B | $-80.0M |
| 总资产 | $9.8B | $1.5B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
| Q4 25 | $233.5M | $421.0M | ||
| Q3 25 | $218.9M | $202.5M | ||
| Q2 25 | $193.1M | $176.3M | ||
| Q1 25 | $237.6M | $127.1M | ||
| Q4 24 | $160.6M | $174.0M | ||
| Q3 24 | $201.7M | $150.6M | ||
| Q2 24 | $261.5M | $480.7M | ||
| Q1 24 | $306.1M | $112.3M |
| Q4 25 | $1.4B | $-80.0M | ||
| Q3 25 | $1.3B | $9.2M | ||
| Q2 25 | $1.3B | $151.3M | ||
| Q1 25 | $1.3B | $144.2M | ||
| Q4 24 | $1.2B | $255.0M | ||
| Q3 24 | $1.2B | $346.8M | ||
| Q2 24 | $1.2B | $432.4M | ||
| Q1 24 | $1.2B | $140.3M |
| Q4 25 | $9.8B | $1.5B | ||
| Q3 25 | $9.9B | $1.2B | ||
| Q2 25 | $9.9B | $1.3B | ||
| Q1 25 | $9.9B | $1.3B | ||
| Q4 24 | $9.8B | $1.5B | ||
| Q3 24 | $9.9B | $1.5B | ||
| Q2 24 | $9.9B | $1.6B | ||
| Q1 24 | $9.9B | $1.3B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $198.3M | $-99.8M |
| 自由现金流经营现金流 - 资本支出 | $191.9M | $-100.8M |
| 自由现金流率自由现金流/营收 | 114.1% | -48.6% |
| 资本支出强度资本支出/营收 | 3.8% | 0.5% |
| 现金转化率经营现金流/净利润 | 4.65× | — |
| 过去12个月自由现金流最近4个季度 | $328.2M | $-472.0M |
8季度趋势，按日历期对齐
| Q4 25 | $198.3M | $-99.8M | ||
| Q3 25 | $52.6M | $-91.4M | ||
| Q2 25 | $49.7M | $-108.3M | ||
| Q1 25 | $37.9M | $-166.5M | ||
| Q4 24 | $178.8M | $-79.3M | ||
| Q3 24 | $43.8M | $-67.0M | ||
| Q2 24 | $50.9M | $-77.0M | ||
| Q1 24 | $35.0M | $-190.7M |
| Q4 25 | $191.9M | $-100.8M | ||
| Q3 25 | $51.1M | $-92.7M | ||
| Q2 25 | $48.4M | $-110.7M | ||
| Q1 25 | $36.8M | $-167.8M | ||
| Q4 24 | $169.7M | $-79.5M | ||
| Q3 24 | $41.7M | $-68.6M | ||
| Q2 24 | $49.0M | $-79.0M | ||
| Q1 24 | $31.9M | $-193.9M |
| Q4 25 | 114.1% | -48.6% | ||
| Q3 25 | 30.1% | -58.0% | ||
| Q2 25 | 28.7% | -66.5% | ||
| Q1 25 | 23.3% | -120.5% | ||
| Q4 24 | 103.0% | -48.3% | ||
| Q3 24 | 24.5% | -49.2% | ||
| Q2 24 | 31.1% | -53.7% | ||
| Q1 24 | 20.8% | -178.2% |
| Q4 25 | 3.8% | 0.5% | ||
| Q3 25 | 0.9% | 0.8% | ||
| Q2 25 | 0.8% | 1.5% | ||
| Q1 25 | 0.7% | 1.0% | ||
| Q4 24 | 5.6% | 0.1% | ||
| Q3 24 | 1.2% | 1.2% | ||
| Q2 24 | 1.2% | 1.4% | ||
| Q1 24 | 2.1% | 3.0% |
| Q4 25 | 4.65× | — | ||
| Q3 25 | 1.11× | — | ||
| Q2 25 | 1.03× | — | ||
| Q1 25 | 0.90× | — | ||
| Q4 24 | 4.63× | — | ||
| Q3 24 | 1.14× | — | ||
| Q2 24 | 1.29× | — | ||
| Q1 24 | 0.99× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
PRK
暂无分部数据
RARE
| Royalty | $105.6M | 51% |
| Products | $101.7M | 49% |
